2m 2m 2m 2m 2m 2m 2m
Alnylam Pharma (ALNY)
NASDAQ
$242.06+$4.96 (+2.09%)
Price as of Aug 28, 2026 7:57 PM EDT- $31.7BMarket Cap
- -46.90%1-Year Change
- BiotechnologyIndustry
Alnylam Pharma (ALNY)
$242.06+$4.96 (+2.09%)
ALNY | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $237.10 | ||
Change | +$0.54 (+0.23%) | ||
Open | $224.47 | ||
High | $239.08 | ||
Low | $223.61 | ||
Previous Close | $236.56 | ||
Volume | 1,847,141 | ||
30-Day Average Volume | 2,300,674 | ||
1-Week Change | 0.37% | ||
1-Month Change | -17.79% | ||
1-Year Change | -46.90% | ||
3-Year Change | 23.71% | ||
5-Year Change | 16.27% | ||
Fundamentals | |||
Shares Outstanding | 133.8M | ||
Total Assets | $5.6B | ||
Market Cap | $31.7B | ||
Enterprise Value | $31.0B | ||
Period: QTR TTM FY | |||
Revenue | $1.2B | ||
Net Income | $164.5M | ||
Free Cash Flow | $292.0M | ||
EBIT | $177.8M | ||
EBITDA | $191.7M | ||
Net Working Capital | $3.1B | ||
EPS | $1.21 | ||
Enterprise Value/EBITDA | 162 | ||
Enterprise Value/Revenue | 26 | ||
P/B | 23 | ||
P/E | 196 | ||
PEG | -10 | ||
Price/Free Cash Flow | 109 | ||
Price/Operating Cash Flow | 97 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue